$1.50
0.00% yesterday
Nasdaq, Aug 12, 09:23 pm CET
ISIN
US87424L1089
Symbol
TLIS

Talis Biomedical Corp Stock price

$1.50
+0.25 20.00% 1M
-0.21 12.28% 6M
-0.26 14.72% YTD
-2.46 62.12% 1Y
-10.43 87.42% 3Y
-238.50 99.38% 5Y
-238.50 99.38% 10Y
-238.50 99.38% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.00 0.00%

Key metrics

Basic
Market capitalization
$47.5m
Enterprise Value
$-12.3m
Net debt
positive
Cash
$59.9m
Shares outstanding
1.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
115.9 | -
EV/Sales
negative | -
EV/FCF
0.3
P/B
1.0
Financial Health
Equity Ratio
73.0%
Return on Equity
-89.7%
ROCE
-71.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$410.0k | $0.0
EBITDA
$-45.6m | $-80.6m
EBIT
$-46.3m | $-72.4m
Net Income
$-51.0m | $-43.3m
Free Cash Flow
$-40.2m
Growth (TTM | estimate)
Revenue
-85.6% | -100.0%
EBITDA
44.8% | -27.4%
EBIT
48.7% | -13.1%
Net Income
40.5% | 30.2%
Free Cash Flow
39.5%
Margin (TTM | estimate)
Gross
95.1%
EBITDA
-11,163.7% | -
EBIT
-11,353.4%
Net
-12,506.4% | -
Free Cash Flow
-9,861.5%
More
EPS
$-28.0
FCF per Share
$-22.1
Short interest
1.5%
Employees
99
Rev per Employee
$20.0k
Show more

Is Talis Biomedical Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Talis Biomedical Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Talis Biomedical Corp forecast:

2x Hold
33%
4x Sell
67%

Analyst Opinions

6 Analysts have issued a Talis Biomedical Corp forecast:

Hold
33%
Sell
67%

Financial data from Talis Biomedical Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
0.41 0.41
86% 86%
100%
- Direct Costs 0.02 0.02
99% 99%
5%
0.39 0.39
153% 153%
95%
- Selling and Administrative Expenses 26 26
19% 19%
6,398%
- Research and Development Expense 20 20
64% 64%
4,995%
-46 -46
45% 45%
-11,110%
- Depreciation and Amortization 0.77 0.77
90% 90%
188%
EBIT (Operating Income) EBIT -46 -46
49% 49%
-11,298%
Net Profit -51 -51
41% 41%
-12,446%

In millions USD.

Don't miss a Thing! We will send you all news about Talis Biomedical Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Talis Biomedical Corp. develops and commercialize innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases. The company was founded on June 26, 2013 and is headquartered in Menlo Park, CA.

Head office United States
CEO Robert Kelley
Employees 99
Founded 2013
Website talisbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today